Stockholm 118 60
Full Time Employees: 2
|Mr. Martin Vidaeus M.B.A., MBA||Founder, CEO & Director||N/A||N/A||1966|
|Mr. Hans Ageland MSEng||Founder & COO||N/A||N/A||1961|
|Mr. Peter Rooslien B.A., BA||Chief Financial Officer||N/A||N/A||1956|
|Mr. Ulf Bjorklund M.Sc.||Chief Medical Officer||N/A||N/A||1956|
Redwood Pharma AB engages in the development of ophthalmic pharmaceutical therapies for unmet market needs. The company's lead development product is RP101, an eye drop that treats severe chronic dry eye disease in post-menopausal women. It uses IntelliGel, a supramolecular smart drug delivery system for development of topical formulation for ophthalmic uses, as well as for administration to the front of the eye. Redwood Pharma AB is based in Stockholm, Sweden.
Redwood Pharma AB’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.